SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 5,162.14 |
| Enterprise Value ($M) | 5,231.48 |
| Book Value ($M) | 5,036.24 |
| Book Value / Share | 32.79 |
| Price / Book | 1.02 |
| NCAV ($M) | -791.10 |
| NCAV / Share | -5.15 |
| Price / NCAV | -6.53 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.12 |
| Return on Assets (ROA) | 0.11 |
| Return on Equity (ROE) | 0.15 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.22 |
| Current Ratio | 1.22 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 769.70 |
| Assets | 6,597.05 |
| Liabilities | 1,560.80 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Genworth Holdings, Inc. | |||
| 13G/A | Bayview Asset Management, Llc | 2.80 | -68.29 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 53,759 | 304,184 | 17.67 | |
| 42,616 | 335,904 | 12.69 | |
| 41,871 | 260,433 | 16.08 | |
| 52,180 | 266,467 | 19.58 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ACAD – ACADIA Pharmaceuticals Inc. | ACLX – Arcellx, Inc. |
| ACRS – Aclaris Therapeutics, Inc. | ADPT – Adaptive Biotechnologies Corporation |
| AGIO – Agios Pharmaceuticals, Inc. |
Financial data and stock pages provided by
Fintel.io